Snapshot from Sep 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug approval

FDA approves daraxonrasib for pancreatic cancer

Analysis based on 92 articles · First reported Aug 26, 2026 · Last updated Aug 29, 2026

Sentiment
80
Attention
7
Articles
92
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval is expected to drive significant revenue for Revolution Medicines, with analysts estimating $28 million in Q3 2026 U.S. sales and $148 million in Q4, and potential annual sales of $11.5 billion. The stock has already risen 166% this year on expectations, and the approval reinforces investor confidence in RAS-targeting therapies, potentially boosting the broader oncology biotech sector.

Biotechnology Pharmaceuticals Healthcare

On August 26, 2026, the U.S. United States — Food and Drug Administration granted expedited approval to daraxonrasib, a first-in-class oral RAS inhibitor developed by Revolution Medicines and marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are ineligible for multiagent chemotherapy. The approval was based on the Phase 3 RASolute 302 trial, which showed a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, a 60% reduction in risk of death, and a doubling of progression-free survival. The drug targets multiple RAS isoforms, including KRAS mutations present in over 90% of pancreatic cancers, a target previously considered 'undruggable.' The FDA approved the drug 6.5 months ahead of its user-fee deadline, under Breakthrough Therapy, Orphan Drug, and Priority Review designations, and the Commissioner's National Priority Voucher pilot program. Revolution Medicines set a wholesale acquisition cost of $39,800 for a 30-day supply. The approval was hailed by oncologists as a landmark advance, with more than 2,000 patients already enrolled in an expanded access program. The drug is also under rolling review by the European Union — European Medicines Agency. Revolution Medicines is studying the technology in other RAS-driven cancers, including lung cancer.

95 Revolution Medicines funded study
90 Revolution Medicines reported trial results
70 Revolution Medicines set list price
70 Kevan Shokat made discovery
60 Revolution Medicines launched expanded access
60 Ben Sasse described drug effectiveness
50 Ben Sasse credited drug
30 Ben Sasse joined
govactor
The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Importance 100.0 Sentiment 80.0
stock
Revolution Medicines received FDA approval for its lead drug daraxonrasib (Rasonque), a first-in-class RAS inhibitor. The approval is expected to drive substantial revenue growth, with analysts projecting up to $11.5 billion in annual sales, and the company's stock has risen 166% this year.
Importance 100.0 Sentiment 90.0
ngo
PanCAN confirmed the approval and expressed concern about patient out-of-pocket costs, advocating for affordable access to the new therapy. The organization supports research into KRAS-targeting drugs.
Importance 40.0 Sentiment 20.0
per
Brian Wolpin led the RASolute 302 trial and presented the results at ASCO, receiving a standing ovation. He called the drug a new standard of care for previously treated metastatic pancreatic cancer.
Importance 40.0 Sentiment 10.0
per
University of California, San Francisco oncologist who called the approval the biggest development in pancreas cancer in decades.
Importance 30.0 Sentiment 0.0
per
Ted Lieu, an oncologist and researcher, authored the article explaining the significance of the approval, contributing to public understanding but not directly involved in the drug's development.
Importance 30.0 Sentiment 50.0
cnt
The United States, through the FDA, approved the drug, making it available to American patients and potentially influencing global regulatory decisions.
Importance 30.0 Sentiment 20.0
per
As acting FDA Commissioner, Kyle Diamantas announced the approval, emphasizing the agency's duty to deliver treatments quickly, and oversaw the expedited review process.
Importance 30.0 Sentiment 10.0
per
The UCSF scientist's foundational discovery enabled the drug's development; he co-founded Revolution Medicines and celebrated the approval.
Importance 30.0 Sentiment 70.0
priv
University medical center whose oncologist praised the approval as a major advance.
Importance 20.0 Sentiment 0.0
ngo
ASCO hosted the presentation of the pivotal trial results, which received a standing ovation, highlighting the significance of the data.
Importance 20.0 Sentiment 50.0
per
Shubham Pant, a trial investigator at MD Anderson, described KRAS as a 'shiny ball' that was previously undruggable, highlighting the scientific breakthrough of the approval.
Importance 20.0 Sentiment 10.0
ngo
City of Hope's Pashtoon Kasi commented that the drug is the best option ever for pancreatic cancer patients, though not a cure, and predicted it will open doors for other companies.
Importance 20.0 Sentiment 10.0
govactor
The EMA is conducting a rolling review of daraxonrasib, which could lead to a marketing authorization application in Europe, expanding the drug's global reach.
Importance 20.0 Sentiment 0.0
per
Former Senator Ben Sasse publicly discussed his positive experience with daraxonrasib on '60 Minutes', raising public awareness and contributing to expanded access demand.
Importance 20.0 Sentiment 10.0
+ 21 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.